Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Lipitor on Aortic Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate calcific AS of a tricuspid or bicuspid aortic valve~* Echocardiographic derived mean pressure gradient \>10 mmHg and an aortic valve area of 0.9 to 1.7 cm2 by continuity equation.~* Laboratory evidence of LDL-c\>70 mg/dl within 12 months prior to recruitment.~Exclusion Criteria:~* Left ventricular ejection fraction \<50%~* Valvular area of 0.9 cm2 and a mean gradient \>30 mmHg~* Rheumatic heart disease~* \>Moderate (2+) aortic insufficiency~* Prior statin therapy to include: \>10 mg of atorvastatin (Lipitor) or \>20 mg of other HMG-CoA Reductase Inhibitors (statins)~* End-stage renal disease (ESRD)~* History of thoracic radiation~* Unable or unwilling to sign informed consent~* Unable to unwilling to return for follow-up~* Other clinically important renal, pulmonary, hepatic, neurological, endocrine, or hematological disorders, vasculitis, or any other situation or medical condition that, in the investigator's opinion, would make survival for the duration of the study unlikely, or would otherwise interfere with optimal participation in the study or produce a significant risk to the patient~* Severe pulmonary hypertension (\>55 mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AORTIC STENOSIS PATIENTS (Type: EXPERIMENTAL): Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis

Based on this trial design, predict the completion outcome and termination type (if applicable).